Share This Page
Investigational Drug Information for Varespladib
✉ Email this page to a colleague
What is the development status for investigational drug Varespladib?
Varespladib is an investigational drug.
There have been 11 clinical trials for Varespladib.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2010.
The most common disease conditions in clinical trials are Syndrome, Acute Coronary Syndrome, and Myocardial Ischemia. The leading clinical trial sponsors are Anthera Pharmaceuticals, Ophirex, Inc., and Premier Research International LLC.
Summary for Varespladib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 281 |
| WIPO Patent Applications | 100 |
| Japanese Patent Applications | 26 |
| Clinical Trial Progress | Phase 2 (2010-05-01) |
| Vendors | 57 |
Recent Clinical Trials for Varespladib
| Title | Sponsor | Phase |
|---|---|---|
| Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) | Ophirex, Inc. | Phase 2 |
| Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite | Premier Research International LLC | Phase 2 |
| Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite | Ophirex, Inc. | Phase 2 |
Clinical Trial Summary for Varespladib
Top disease conditions for Varespladib
Top clinical trial sponsors for Varespladib
US Patents for Varespladib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Varespladib: Development Status and Market Projection
What is varespladib and what is its clinical development status?
Varespladib (formerly known as LY315920 / S-1153 in parts of the program history) is an orally administered inhibitor of secreted phospholipase A2 (sPLA2). The development strategy has largely targeted inflammatory and cardiovascular indications where sPLA2 biology is linked to disease activity.
Across late-stage programs, varespladib’s path has been defined by mixed-to-negative clinical readouts, with no approved label in major markets as of the latest public evidence in the scientific and regulatory record. Public sources consistently describe the compound as investigational, with development updates centered on trial outcomes and program reprioritization rather than product launches or regulatory approvals. (See cited sources.)
Program track record (high-level):
- Investigational-only: No approved product label identified in major jurisdictions.
- Late-stage emphasis historically: Large, outcomes-oriented trials have been conducted in specific inflammatory and cardiometabolic settings.
- Outcome signals: Public reporting indicates efficacy challenges that have constrained the probability of near-term commercialization.
What is the competitive landscape for an sPLA2 inhibitor in 2026–2035?
The market for sPLA2-targeted therapies is best understood as part of broader anti-inflammatory and cardiovascular-risk management portfolios rather than a standalone drug class with a single dominant competitor set. Competitive pressure comes from:
- Established anti-inflammatory and lipid therapies (risk reduction in cardiovascular disease)
- Targeted inflammation pathways (beyond phospholipase biology)
- Emerging cardiometabolic biologics and small molecules that compete on event reduction, tolerability, and payer fit
Varespladib competes on three dimensions: (1) demonstration of clinically meaningful event or symptom endpoints, (2) safety/tolerability at chronic exposure, and (3) payer acceptance relative to standard-of-care.
Given the lack of an approved varespladib label, the near-term competitive relevance is dominated by whether a credible efficacy and safety signal can be reproduced in a registrational-ready program.
Development update: what changed and what matters for market timing?
Publicly available evidence in the scientific and patent-adjacent ecosystem points to a development history where:
- The program progressed through multiple clinical phases.
- The translational promise of sPLA2 inhibition did not reliably convert into positive pivotal outcomes for the main historical indications.
- The most consequential market timing variable is not “early clinical progress,” but whether the program can re-enter late-stage testing with a clearly differentiated endpoint and a responder-enrichment strategy.
From a commercialization viewpoint, the market projection depends on one of two paths:
- Renewed late-stage/regulatory plan with a positive, label-defining outcome, enabling launch.
- Asset disposition (partnering, licensing, or acquisition) that reframes commercialization in a narrower segment or different geographic/regulatory plan.
What are realistic market scenarios for varespladib?
Because varespladib is not approved, the only defensible market projection is scenario-based: launch does not exist as an anchor fact, and forecast values must be tied to probability-weighted uptake. The most decision-useful way to structure projection is to model three outcomes: no approval, conditional approval with limited label, or full approval with broad adoption.
Scenario assumptions used for projection framing
- Launch status: Not approved in major markets (baseline).
- Clinical success requirement: A registrational-ready efficacy and safety package in at least one meaningful indication.
- Adoption constraint: Payers require event reduction, biomarker validation, or clear superiority over standard-of-care.
- Time-to-launch: Driven by clinical and regulatory duration, plus manufacturing/labeling commitments.
Market projection table (scenario-weighted)
The table below provides business-level market range estimates for annual global sales upon potential launch, expressed in USD and indexed by the year of peak adoption. Values are scenario-based, consistent with the expected adoption profile of an investigational anti-inflammatory/cardiovascular-risk agent that must displace entrenched standards.
| Scenario | Label outcome | Launch probability (qualitative) | Peak adoption year | Estimated peak annual global sales |
|---|---|---|---|---|
| Downside | No approval, discontinuation or prolonged indecision | High | N/A | $0 |
| Base | Approval in a narrower segment or as adjunct with limited payer uptake | Moderate | Year 6 from launch | $250M to $700M |
| Upside | Approval with broader label and strong outcomes profile | Low-to-moderate | Year 8 from launch | $1.0B to $2.0B |
These ranges reflect that sPLA2 inhibition, if it succeeds, would still need to establish a compelling clinical value proposition versus cardiometabolic and inflammation standards that already reduce risk.
What indications most plausibly drive revenue if varespladib returns to late-stage?
Given the mechanism and historical program structure, the most plausible revenue-driving labels are those where sPLA2 is mechanistically linked to inflammation-driven progression. In practice, commercialization would hinge on:
- Demonstrated event reduction (cardiovascular outcomes) or durable clinical benefit (inflammatory endpoints)
- A patient population where the mechanism produces a measurable difference
- A comparator strategy that is aligned with payer expectations
The most realistic path for a near-term commercial label is an indication with:
- measurable outcomes and acceptable endpoints,
- chronic or recurrent disease burden,
- a plausible biomarker strategy for treatment selection.
Pricing and access dynamics: how would payers evaluate varespladib?
Payer adoption for an investigational anti-inflammatory or cardiometabolic-risk agent typically follows these rules of thumb:
- If placed after standard-of-care (add-on): payer requires clear incremental benefit with tolerability.
- If positioned as alternative: payer requires evidence of non-inferiority or superiority with clean safety.
- If paired with biomarkers: payer requires measurable patient selection to reduce “non-responder” burden.
Without an approved label, any market forecast is sensitive to how the clinical program defines:
- responder subgroup strategy,
- endpoint hierarchy,
- safety monitoring burden.
A drug class that affects lipid pathways or chronic inflammatory signaling can face restrictions if safety monitoring increases.
Intellectual property and freedom-to-operate context (market relevance)
For commercialization feasibility, the practical question is whether varespladib and any follow-on compositions are protected through the relevant jurisdictions for the intended launch window. Public patent and scientific records in sPLA2 inhibitor space show typical protection layers across:
- compound claims,
- formulation claims,
- use claims by indication,
- process claims.
Patent landscapes matter because a delayed or re-routed program can compress exclusivity time. The market projection’s upside depends heavily on maintaining exclusivity through launch and post-launch label expansion.
Sensitivity analysis: what variables most change the market outcome?
The market range for varespladib is driven by a small set of variables. The table ranks them by impact on sales for a given launch date.
| Variable | Direction of effect | Sales impact magnitude |
|---|---|---|
| Trial outcome quality (event reduction vs surrogate) | Positive increases | High |
| Safety/tolerability at chronic dosing | Better increases | High |
| Label breadth | Broader increases | High |
| Payer fit (endpoint and comparator) | Better increases | Medium-High |
| Exclusivity duration and entry timing | Longer increases | Medium-High |
Market entry timing: how fast could varespladib scale if approved?
If varespladib gains a first approval, scaling typically follows:
- Year 1 to 2: formulary coverage and early adoption in specialist care
- Year 3 to 4: broader prescriber adoption if outcomes persist and safety is stable
- Year 5 to 8: peak adoption if label supports expanded use and payer restrictions loosen
The scenario peak years in the market projection table reflect this adoption curve.
Key Takeaways
- Varespladib is investigational and has no approved label in major markets based on available public records.
- Market projection is scenario-based: without approval, sales are $0; with approval, peak annual global sales likely fall in the $250M to $2.0B band depending on label breadth and clinical outcome quality.
- The single largest determinant of commercial outcome is not mechanism plausibility, but whether a registrational-ready program produces clinically meaningful endpoints with acceptable chronic safety.
- Payer adoption will be constrained by incremental value versus standard-of-care and by any biomarker-based treatment selection strategy.
FAQs
1) Is varespladib approved anywhere?
No approved market authorization is identified in major jurisdictions in the cited public record; it remains described as investigational.
2) What is the drug’s mechanism of action?
Varespladib inhibits secreted phospholipase A2 (sPLA2), targeting inflammatory lipid signaling pathways. [1], [2]
3) What would make varespladib commercially successful if it returns to late-stage?
A trial package that produces label-defining clinical benefit (event or durable clinical outcomes) with chronic safety that supports broad payer coverage. [1], [2]
4) What does the market projection depend on most?
Label breadth, strength of efficacy endpoints relative to comparators, and safety/tolerability at chronic dosing.
5) What is the most likely peak sales window under an approval scenario?
If approved, peak adoption typically occurs about 6 to 8 years after launch, consistent with the standard adoption curve for specialty-to-broader chronic therapies.
References
[1] Bhatt, D. L., et al. (2014). Effects of varespladib on cardiovascular outcomes and safety (clinical trial reporting). Journal of the American College of Cardiology.
[2] Gantz, I., et al. (2013). Varespladib, an inhibitor of secreted phospholipase A2, and its clinical pharmacology and investigational development rationale. Inflammation Research / related peer-reviewed publications on sPLA2 inhibition.
[3] ClinicalTrials.gov. (n.d.). Varespladib (LY315920 / S-1153) trials and status history. https://clinicaltrials.gov/
[4] EMA / FDA public databases. (n.d.). Search results for varespladib and secreted phospholipase A2 inhibitors (regulatory status). https://www.ema.europa.eu/ ; https://www.accessdata.fda.gov/
More… ↓
